cTAPcTAPcTAPcTAP
  • WHAT WE DO
  • WHO WE ARE
  • HOW WE DO IT
  • NEWS
  • CONTACT
  • IS cTAP FOR YOU?
    • Biopharmaceutical Companies
    • Scientific Leaders & Researchers
    • Patient Organizations

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials

Craig M. McDonald, MD, Gautam Sajeev, ScD, Zhiwen Yao, BA, Erin McDonnell, MS, Gary Elfring, MS, Marcio Souza, PharmD, MBA, Stuart W. Peltz, PhD, Basil T. Darras, MD, Perry B. Shieh, MD, PhD, David A. Cox, PhD, John Landry, MMath, James Signorovitch, PhD, and for the ACT DMD Study Group and the Tadalafil DMD Study Group. Muscle Nerve. 2020 Jan; 61(1): 26–35.

View the PDF

10
Jan 2020
Publications

Read the latest

  • Prognostic factors for loss of ability to rise from supine in DMD
  • Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
  • cTAP Study Shows Real-World, Natural History Data Comparable to Placebo Data from Clinical Trials in Duchenne Muscular Dystrophy
  • A prognostic model for 1 year change in 4SC
  • Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

COLLABORATIVE TRAJECTORY
ANALYSIS PROJECT

Cambridge Innovative Center
One Broadway, Cambridge, MA 02142

T: 617-555-5555
E: info@ctap-duchenne.org

© 2021 Collaborative Trajectory Analysis Project. All rights reserved.

  • WHAT WE DO
  • WHO WE ARE
  • HOW WE DO IT
  • NEWS
  • CONTACT
  • IS cTAP FOR YOU?
    • Biopharmaceutical Companies
    • Scientific Leaders & Researchers
    • Patient Organizations